EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Anakinra-Loaded Sphingomyelin Nanosystems Modulate In Vitro IL-1-Dependent Pro-Tumor Inflammation in Pancreatic Cancer

Marcelina Abal-Sanisidro iD, Michele De Luca iD, Stefania Roma, Maria Grazia Ceraolo iD, Maria de la Fuente iD, Lucia De Monte iD, Maria Pia Protti iD

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms25158085 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Marcelina Abal-Sanisidro und 6 weiteren Autor:innen. Beteiligte Einrichtung: Nano-Oncology and Translational Therapeutics Group, Health Research Institute of Santiago de Compostela (IDIS), SERGAS, 15706 Santiago de Compostela,…. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Interleukin 1 Receptor Antagonist Protein, Interleukin-1, Sphingomyelins. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Italian Ministry of Health, Italian Association for Cancer Research, Instituto de Salud Carlos III and European Regional Development Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pancreatic cancer is a very aggressive disease with a dismal prognosis. The tumor microenvironment exerts immunosuppressive activities through the secretion of several cytokines, including interleukin (IL)-1. The IL-1/IL-1 receptor (IL-1R) axis is a key regulator in tumor-promoting T helper (Th)2- and Th17-type inflammation. Th2 cells are differentiated by dendritic cells endowed with Th2-polarizing capability by the thymic stromal lymphopoietin (TSLP) that is secreted by IL-1-activated cancer-associated fibroblasts (CAFs). Th17 cells are differentiated in the presence of IL-1 and other IL-1-regulated cytokines. In pancreatic cancer, the use of a recombinant IL-1R antagonist (IL1RA, anakinra, ANK) in in vitro and in vivo models has shown efficacy in targeting the IL-1/IL-1R pathway. In this study, we have developed sphingomyelin nanosystems (SNs) loaded with ANK (ANK-SNs) to compare their ability to inhibit Th2- and Th17-type inflammation with that of the free drug in vitro. We found that ANK-SNs inhibited TSLP and other pro-tumor cytokines released by CAFs at levels similar to ANK. Importantly, inhibition of IL-17 secretion by Th17 cells, but not of interferon-γ, was significantly higher, and at lower concentrations, with ANK-SNs compared to ANK. Collectively, the use of ANK-SNs might be beneficial in reducing the effective dose of the drug and its toxic effects.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsInterleukin 1 Receptor Antagonist ProteinInterleukin-1SphingomyelinsHumansCytokinesCell Line, TumorInflammationTh17 CellsTh2 CellsTumor MicroenvironmentNanoparticlesCancer-Associated Fibroblasts

Stichwörter der Autor:innen

IFN-γIL-1IL-17IL-1RATSLPpancreatic ductal adenocarcinomasphingomyelin nanosystems

Substanzen

Interleukin 1 Receptor Antagonist ProteinInterleukin-1SphingomyelinsCytokines

Autor:innen und Institutionen

  • Nano-Oncology and Translational Therapeutics Group, Health Research Institute of Santiago de Compostela (IDIS), SERGAS, 15706 Santiago de Compostela, Spain.
  • University of Santiago de Compostela (USC), 15782 Santiago de Compostela, Spain.
  • Biomedical Research Networking Center on Oncology (CIBERONC), 28029 Madrid, Spain.
  • Tumor Immunology Unit, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) San Raffaele Scientific Institute, 20132 Milan, Italy.
  • Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy.
  • DIVERSA Technologies S.L., Edificio Emprendia, Campus Sur, 15782 Santiago de Compostela, Spain.

ORCID-Profile: Marcelina Abal-Sanisidro, Michele De Luca, Maria Grazia Ceraolo, Maria de la Fuente, Lucia De Monte, Maria Pia Protti

Förderung

  • Italian Ministry of Health
  • Italian Association for Cancer Research
  • Instituto de Salud Carlos III and European Regional Development Fund
  • Instituto de Salud Carlos III
  • Instituto de Salud Carlos III (ISCIII) and the European Regional Development Fund (FEDER)
  • Health Research Institute of Santiago de Compostela (IDIS)

Zitieren

APA

Abal-Sanisidro, M., De Luca, M., Roma, S., Ceraolo, M. G., de la Fuente, M., De Monte, L., & Protti, M. P. (2024). Anakinra-Loaded Sphingomyelin Nanosystems Modulate In Vitro IL-1-Dependent Pro-Tumor Inflammation in Pancreatic Cancer. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25158085

Vancouver

Abal-Sanisidro M, De Luca M, Roma S, Ceraolo MG, de la Fuente M, De Monte L, et al. Anakinra-Loaded Sphingomyelin Nanosystems Modulate In Vitro IL-1-Dependent Pro-Tumor Inflammation in Pancreatic Cancer. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25158085

BibTeX
@article{AbalSanisidro2024,
  author = {Abal-Sanisidro, Marcelina and De Luca, Michele and Roma, Stefania and Ceraolo, Maria Grazia and de la Fuente, Maria and De Monte, Lucia and Protti, Maria Pia},
  title = {Anakinra-Loaded Sphingomyelin Nanosystems Modulate In Vitro IL-1-Dependent Pro-Tumor Inflammation in Pancreatic Cancer},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms25158085}
}
Kostenlos starten →